Immunosuppressive therapy after kidney transplantation;Immunsuppressive therapie nach nierentransplantation

Pharmazie in Unserer Zeit

Volumn 34, Issue 4, 2005, Pages 322-331

  Griebsch, Ingolf ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; AZATHIOPRINRATIOPHARM; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; IMMUREK; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; SANDIMMUN OPTORAL; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; ZYTRIM;

COST BENEFIT ANALYSIS; EPIDEMIOLOGICAL DATA; GERMANY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; REVIEW; STEROID THERAPY;

EID: 22244438585     PISSN: 00483664     EISSN: None     Source Type: Journal    
DOI: 10.1002/pauz.200500132     Document Type: Review

References (37)

1. Nebel M.: Kosten der Nierenersatztherapie (2003): In: Hoerl, W.H., Wanner C. (Eds.) Dialyseverfahren in Theorie und Praxis. Thieme, Stuttgart, pp. 619-629.
2. Boehler, J.: Nierentransplantation (2003). In: Kuhlmann, U., Walb D., Luft F.C. (Eds.) Nephrologie: Pathophysiologie - Klinik - Nierenersatzverfahren. Thieme, Stuttgart, pp. 588-638.
3. Reimer, J., Franke, G.H., Lutkes, P., et al.: Quality of life in patients before and after kidney transplantation. Psychother. Psychosom. Med. Psychol. 52 (2002), 16-23.
4. Wolfe, R.A., Ashby, V.B., Milford, E.L., et al.: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 341 (1999), 1725-1730.
5. Vianello, A., Spinello, M., Palminteri, C., Brunello, A., Calconi, C., Maresca, M.C.: Are the baseline chances of survival comparable between the candidates for kidney transplantation who actually receive a graft and those who never get one? Nephrol. Dial. Transplant. 17 (2002), 1093-1098.
6. Winkelmayer, W.C., Weinstein, M.C., Mittleman, M.A., Glynn, R.J., Pliskin, J.S.: Health economic evaluations: the special case of end-stage renal disease treatment. Med. Decis. Making 22 (2002), 417-430.
7. Nagel, E., Niechzial, M.: Bewertung chirurgischer Therapien. Springer Berlin, Heidelberg, New York, Barcelona, Hongkong, London, Mailand, Paris, Singapur, Tokio (1999).
8. Frei, U., Schober-Halstenberg, H.J.: Nierenersatztherapie in Deutschland. QuaSi-Niere Jahresbericht 2003/2004, Berlin (2005).
9. Organspende und Transplantation in Deutschland: Neu-Isenburg: Deutsche Stiftung Organtransplantation (2004).
10. Hagenmeyer, E.G., Haussler, B., Hempel, E., et al.: Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications. Transplantation 77 (2004), 1545-1550.
11. Offermann, G.: Immunosuppression for long-term maintenance of renal allograft function. Drugs 64 (2004), 1325-1338.
12. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B.: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4 (2004), 378-383.
13. OPTN/SRTR 2003 Annual Report: Chapter IV: Immunosuppression Practice and Trends. http://www.optn.org/AR2003/Chapter_IV_AR_Print.pdf
14. Webster, A.C., Playford, E.G., Higgins, G., Chapman, J.R., Craig, J.: Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst. Rev. (2004); CD003897.
15. Schnitzler, M.A., Woodward, R.S., Lowell, J.A., Singer, G.G., Brennan, D.C.: Ten-year cost effectiveness of alternative immunosuppression regimens in cadaveric renal transplantation. Transplant. Proc. 31 (1999), 19S-21S.
16. Walters, S.J., Whitfield, M., Akehurst, R.L., Chilcott, J.B.: Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspective. Pharmacoeconomics 21 (2003), 129-138.
17. Walters, S.J., Whitfield, M., Akehurst, R.L., Chilcott, J.B.: Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients. Transplant. Proc. 33 (2001), 3187-3191.
18. Keown, P.A., Balshaw, R., Krueger, H., Baladi, J.F.: Economic analysis of basiliximab in renal transplantation. Transplantation 71 (2001), 1573-1579.
19. Polsky, D., Weinfurt, K.P., Kaplan, B., Kim, J., Fastenau, J., Schulman, K.A.: An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation. Nephrol. Dial. Transplant. 16 (2001), 1028-1033.
20. Chilcott, J.B., Holmes, M.W., Walters, S., Akehurst, R.L., Nashan, B.: The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation. Transpl. Int. 15 (2002), 486-493.
21. Lorber, M.I., Fastenau, J., Wilson, D., Di Cesare, J., Hall, M.L.: A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation. Clin. Transplant. 14 (2000), 479-485.
22. National Institute for Clinical Excellence (NICE). TA085 Renal transplantation - immuno-suppressive regimens (review) - Guidance. http://www.nice.org.uk/pdf/TA085guidance.pdf
23. Orme, M.E., Jurewicz, W.A., Kumar, N., McKechnie, T.L.: The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Pharmacoeconomics 21 (2003), 1263-1276.
24. Hacker, J., Ponner, B., Schindler, T., Oberender, P.: Bessere Kosteneffektivitaet von Tacrolimus versus Ciclosporin-Microemulsion in der Nierentransplantation- Eine oekonomische Analyse. Transplantationsmedizin (2003), s67-s68.
25. Craig, A.M., McKechnie, T., McKenna, M., Klein, W., Schindler, T.M.: A cost-effectiveness analysis of tacrolimus versus cyclosporine microemulsion following kidney transplantation. Transplant. Proc. 34(2002), 1646-1648.
26. Lazzaro, C., McKechnie, T., McKenna, M.: Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses. J. Nephrol. 15 (2002), 580-588.
27. Sperschneider, H.: A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. Transplant. Proc. 33 (2001), 1279-1281.
28. Keown, P.: Analysis of cost-effectiveness and cost-utility for immunosuppressive protocols in renal transplantation. Transplant. Proc. 31 (1999), 1140-1141.
29. Holmes, M., Chilcott, J., Walters, S., Whitby, S., Akehurst, R.: Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. Transpl. Int. 17 (2004), 182-187.
30. Schwabe, U., Paffrath, D.: Arzneimittelverordnungsreport 2004, Springer, Berlin, Heidelberg (2004).
31. Lilliu, H., Brun, C., Le, P.C., et al.: Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction. Transplant. Proc. 33 (2001), 3197-3198.
32. Morris-Stiff, G., Richards, T., Singh, J., et al.: Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. Transplant. Proc. 30 (1998), 1285-1286.
33. Neylan, J.F., Sullivan, E.M., Steinwald, B., Goss, T.F.: Assessment of the frequency and costs of posttransplantation hospitalizations in patients receiving tacrolimus versus cyclosporine. Am. J. Kidney Dis. 32 (1998); 770-777.
34. Sullivan, S.D., Garrison, L.P., Jr., Best, J.H.: The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group. J. Am. Soc. Nephrol. (1997), 1592-1598.
35. Khosla, U.M., Martin, J.E., Baker, G.M., Schroeder, T.J., First, M.R.: One-year, single-center cost analysis of mycophenolate mofetil versus azathioprine following cadaveric renal transplantation. Transplant. Proc. 31 (1999), 274-275.
36. Baker, G.M., Martin, J.E., Jang, R., et al.: Pharmacoeconomic analysis of mycophenolate mofetil versus azathioprine in primary cadaveric renal transplantation. Transplant. Proc. 30 (1998), 4082-4084.
37. Suleymanlar, G., Tuncer, M., Sarikaya, M., et al.: The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation. Transplant. Proc. 33 (2001), 2780-2781.